Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R

•The FEOS score and Upham criteria are useful tools that help the clinician in clinical practice.•Both tools can help to make a decision in maintain or discontinue the biologic treatment.•FEOS=75 could be the suitable cut-off point to identify super-responders.•We may wait until second year to evalu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Respiratory medicine 2023-05, Vol.211, p.107216-107216, Article 107216
Hauptverfasser:	Laorden, Daniel, Zamarrón, Ester, Romero, David, Domínguez-Ortega, Javier, Villamañán, Elena, Losantos, Itsaso, Gayá, Francisco, Quirce, Santiago, Álvarez-Sala, Rodolfo
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Asthmatic Agents - therapeutic use Anti-IL5 Anti-IL5R Asthma Asthma - drug therapy Asthma remission Benralizumab Biologic treatment FEOS score Humans Mepolizumab Reslizumab Super-responder
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!